CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.68 billion. The enterprise value is $2.53 billion.
| Market Cap | 1.68B |
| Enterprise Value | 2.53B |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CONMED has 30.95 million shares outstanding. The number of shares has decreased by -0.79% in one year.
| Current Share Class | 30.95M |
| Shares Outstanding | 30.95M |
| Shares Change (YoY) | -0.79% |
| Shares Change (QoQ) | -0.31% |
| Owned by Insiders (%) | 0.85% |
| Owned by Institutions (%) | 114.82% |
| Float | 30.68M |
Valuation Ratios
The trailing PE ratio is 15.35 and the forward PE ratio is 11.90. CONMED's PEG ratio is 1.80.
| PE Ratio | 15.35 |
| Forward PE | 11.90 |
| PS Ratio | 1.27 |
| Forward PS | 1.17 |
| PB Ratio | 1.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.35 |
| P/OCF Ratio | 10.19 |
| PEG Ratio | 1.80 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.50, with an EV/FCF ratio of 17.07.
| EV / Earnings | 22.96 |
| EV / Sales | 1.91 |
| EV / EBITDA | 11.50 |
| EV / EBIT | 17.02 |
| EV / FCF | 17.07 |
Financial Position
The company has a current ratio of 2.23, with a Debt / Equity ratio of 0.88.
| Current Ratio | 2.23 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | 3.85 |
| Debt / FCF | 5.95 |
| Interest Coverage | 4.34 |
Financial Efficiency
Return on equity (ROE) is 11.69% and return on invested capital (ROIC) is 4.98%.
| Return on Equity (ROE) | 11.69% |
| Return on Assets (ROA) | 4.03% |
| Return on Invested Capital (ROIC) | 4.98% |
| Return on Capital Employed (ROCE) | 7.31% |
| Revenue Per Employee | $340,063 |
| Profits Per Employee | $28,255 |
| Employee Count | 3,900 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, CONMED has paid $27.49 million in taxes.
| Income Tax | 27.49M |
| Effective Tax Rate | 19.97% |
Stock Price Statistics
The stock price has decreased by -23.14% in the last 52 weeks. The beta is 1.17, so CONMED's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -23.14% |
| 50-Day Moving Average | 52.24 |
| 200-Day Moving Average | 60.25 |
| Relative Strength Index (RSI) | 53.74 |
| Average Volume (20 Days) | 457,504 |
Short Selling Information
The latest short interest is 846,967, so 2.74% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.74% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 3.37 |
Income Statement
In the last 12 months, CONMED had revenue of $1.33 billion and earned $110.20 million in profits. Earnings per share was $3.54.
| Revenue | 1.33B |
| Gross Profit | 743.42M |
| Operating Income | 148.67M |
| Pretax Income | 123.90M |
| Net Income | 110.20M |
| EBITDA | 220.07M |
| EBIT | 148.67M |
| Earnings Per Share (EPS) | $3.54 |
Balance Sheet
The company has $33.94 million in cash and $881.83 million in debt, giving a net cash position of -$847.89 million or -$27.39 per share.
| Cash & Cash Equivalents | 33.94M |
| Total Debt | 881.83M |
| Net Cash | -847.89M |
| Net Cash Per Share | -$27.39 |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 32.41 |
| Working Capital | 362.94M |
Cash Flow
In the last 12 months, operating cash flow was $165.21 million and capital expenditures -$16.97 million, giving a free cash flow of $148.24 million.
| Operating Cash Flow | 165.21M |
| Capital Expenditures | -16.97M |
| Free Cash Flow | 148.24M |
| FCF Per Share | $4.79 |
Margins
Gross margin is 56.05%, with operating and profit margins of 11.21% and 8.31%.
| Gross Margin | 56.05% |
| Operating Margin | 11.21% |
| Pretax Margin | 10.38% |
| Profit Margin | 8.31% |
| EBITDA Margin | 16.59% |
| EBIT Margin | 11.21% |
| FCF Margin | 11.18% |
Dividends & Yields
This stock pays an annual dividend of $0.80, which amounts to a dividend yield of 1.47%.
| Dividend Per Share | $0.80 |
| Dividend Yield | 1.47% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 22.60% |
| Buyback Yield | 0.79% |
| Shareholder Yield | 2.26% |
| Earnings Yield | 6.55% |
| FCF Yield | 8.81% |
Analyst Forecast
The average price target for CONMED is $59.80, which is 10.01% higher than the current price. The consensus rating is "Hold".
| Price Target | $59.80 |
| Price Target Difference | 10.01% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.22 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 7 |